{
  "id": "61f5ffc8882a024a1000001d",
  "type": "summary",
  "question": "What is CIS43LS?",
  "ideal_answer": "CIS43LS is an antimalarial monoclonal antibody with an extended half-life against infection with Plasmodium falciparum.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
    "http://www.ncbi.nlm.nih.gov/pubmed/34511592",
    "http://www.ncbi.nlm.nih.gov/pubmed/33332286"
  ],
  "snippets": [
    {
      "text": ". On August 26, 2021, the findings from a phase 1 trial on a new monoclonal antibody to PfCSP, CIS43LS, showed that a single dose of the CIS43LS monoclonal antibody resulted in protection against malaria. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on these data, CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33332286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: We conducted a two-part, phase 1 clinical trial to assess the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ion or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection. (Funded by the National Institute of Allergy and Infectio",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e findings from a phase 1 trial on a new monoclonal antibody to PfCSP, CIS43LS, showed that a single dose of the CIS43LS monoclonal antibody resulted in protection against malaria. These new findings have ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "by malaria.METHODS: We conducted a two-part, phase 1 clinical trial to assess the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Pl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Additional interventions are needed to reduce the morbidity and mortality caused by malaria.METHODS: We conducted a two-part, phase 1 clinical trial to assess the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with P",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On August 26, 2021, the findings from a phase 1 trial on a new monoclonal antibody to PfCSP, CIS43LS, showed that a single dose of the CIS43LS monoclonal antibody resulted in protection against malaria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "lled human malaria infection. Two participants who received 40 mg per kilogram of CIS43LS and underwent controlled human malaria infection approximately 36 weeks later had no parasitemia, with serum concentrations of CIS43LS of 46 and 57 \u03bcg per milliliter at the time of controlled human malaria infection.CONCLUSIONS: Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS pr",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}